Reproductive Embryo Editing: Attending to Justice
By Inmaculada De Melo-Martín,
The Hastings Center Report
| 08. 22. 2022
Advances in genome editing technologies allow scientists to add, remove, or alter genetic material at particular locations in the human genome. Genome editing of somatic cells offers great promise in the prevention and treatment of various human diseases. But these technologies could also be used to modify gametes and embryos. Some commentators defend gene editing for reproductive purposes on the ground that it would allow people who are at risk of transmitting genetic diseases to their offspring to have healthy and genetically related children.
Using gene editing in this way would require further research. The technology still presents problems involving off-target effects and reliability. Researchers must improve delivery to desired tissues and control of immunogenic reactions. Yet I argue here that, if we accept certain background claims about justice, accepting the goal of helping people have healthy and genetically related children should commit one to rejecting the investment of social resources into further development of reproductive embryo editing.
Considerations of justice are relevant to questions regarding the development of reproductive embryo editing for several reasons. First, decisions about research-funding priorities involve...
Related Articles
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...
By Emily Glazer, Katherine Long, Amy Dockser Marcus, The Wall Street Journal | 11.08.2025
For months, a small company in San Francisco has been pursuing a secretive project: the birth of a genetically engineered baby.
Backed by OpenAI chief executive Sam Altman and his husband, along with Coinbase co-founder and CEO Brian Armstrong, the startup—called...
By Heidi Ledford, Nature | 10.31.2025
Late last year, dozens of researchers spanning thousands of miles banded together in a race to save one baby boy’s life. The result was a world first: a cutting-edge gene-editing therapy fashioned for a single person, and produced in...
By Lauran Neergaard, AP News | 11.03.2025
WASHINGTON (AP) — The first clinical trial is getting underway to see if transplanting pig kidneys into people might really save lives.
United Therapeutics, a producer of gene-edited pig kidneys, announced Monday that the study’s initial transplant was performed successfully...